Potential protective effects of Huanglian Jiedu Decoction against COVID-19-associated acute kidney injury: A network-based pharmacological and molecular docking study.
COVID-19
Huanglian Jiedu Decoction
acute kidney injury
network pharmacology
Journal
Open medicine (Warsaw, Poland)
ISSN: 2391-5463
Titre abrégé: Open Med (Wars)
Pays: Poland
ID NLM: 101672167
Informations de publication
Date de publication:
2023
2023
Historique:
received:
05
01
2023
revised:
06
06
2023
accepted:
16
06
2023
medline:
3
8
2023
pubmed:
3
8
2023
entrez:
3
8
2023
Statut:
epublish
Résumé
Corona virus disease 2019 (COVID-19) is prone to induce multiple organ damage. The kidney is one of the target organs of SARS-CoV-2, which is susceptible to inducing acute kidney injury (AKI). Huanglian Jiedu Decoction (HLJDD) is one of the recommended prescriptions for COVID-19 with severe complications. We used network pharmacology and molecular docking to explore the therapeutic and protective effects of HLJDD on COVID-19-associated AKI. Potential targets related to "HLJDD," "COVID-19," and "Acute Kidney Injury/Acute Renal Failure" were identified from several databases. A protein-protein interaction (PPI) network was constructed and screened the core targets according to the degree value. The target genes were then enriched using gene ontology and Kyoto Encyclopedia of Genes and Genomes. The bioactive components were docked with the core targets. A total of 65 active compounds, 85 common targets for diseases and drugs were obtained; PPI network analysis showed that the core protein mainly involved JUN, RELA, and AKT1; functional analysis showed that these target genes were mainly involved in lipid and atherosclerosis signaling pathway and IL-17 signal pathway. The results of molecular docking showed that JUN, RELA, and AKT1 had good binding activity with the effective chemical components of HLJDD. In conclusion, HLJDD can be used as a potential therapeutic drug for COVID-19-associated AKI.
Identifiants
pubmed: 37533739
doi: 10.1515/med-2023-0746
pii: med-2023-0746
pmc: PMC10390755
doi:
Types de publication
Journal Article
Langues
eng
Pagination
20230746Informations de copyright
© 2023 the author(s), published by De Gruyter.
Déclaration de conflit d'intérêts
Conflict of interest: Authors state no conflict of interest.
Références
Cancers (Basel). 2022 Oct 14;14(20):
pubmed: 36291831
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Comput Biol Med. 2022 May;144:105389
pubmed: 35303581
Andrologia. 2021 Oct;53(9):e14165
pubmed: 34185887
Phytomedicine. 2022 Jan;95:153777
pubmed: 34815154
Crit Care. 2020 Jun 19;24(1):365
pubmed: 32560665
Trends Pharmacol Sci. 2022 Feb;43(2):136-150
pubmed: 34895945
Front Pharmacol. 2021 Nov 19;12:761980
pubmed: 34867383
J Med Virol. 2021 Dec;93(12):6641-6652
pubmed: 34314040
Database (Oxford). 2017 Jan 1;2017:
pubmed: 28605766
J Am Soc Nephrol. 2021 Nov;32(11):2851-2862
pubmed: 34470828
Front Cell Dev Biol. 2022 Jan 19;9:740266
pubmed: 35127697
Pharmacogenomics. 2008 Aug;9(8):1155-62
pubmed: 18681788
Life Sci. 2020 Aug 1;254:117735
pubmed: 32360572
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Front Mol Biosci. 2023 Feb 27;10:1065171
pubmed: 36923645
Evid Based Complement Alternat Med. 2022 Oct 5;2022:1672670
pubmed: 36248427
Emerg Microbes Infect. 2020 Dec;9(1):1123-1130
pubmed: 32475230
Aging (Albany NY). 2021 Jun 4;13(11):14571-14589
pubmed: 34088885
Front Endocrinol (Lausanne). 2022 Oct 18;13:978601
pubmed: 36329882
Kidney Int. 2020 May;97(5):829-838
pubmed: 32247631
Am J Rhinol Allergy. 2022 Sep;36(5):638-648
pubmed: 35585694
PLoS Pathog. 2022 Oct 3;18(10):e1010640
pubmed: 36191034
Am J Chin Med. 2021;49(5):1017-1044
pubmed: 34107860
Intensive Care Med. 2020 Jun;46(6):1114-1116
pubmed: 32236644
Chin J Integr Med. 2020 Jan;26(1):72-80
pubmed: 30941682
Mol Med Rep. 2018 May;17(5):7395-7402
pubmed: 29568860
Kidney Int. 2020 Jul;98(1):219-227
pubmed: 32327202
Int J Mol Sci. 2023 Feb 23;24(5):
pubmed: 36901832
Front Immunol. 2022 Sep 09;13:986346
pubmed: 36159817
Biochem Pharmacol. 2018 Aug;154:203-212
pubmed: 29753749
Nat Rev Nephrol. 2020 Jun;16(6):308-310
pubmed: 32273593
Phytother Res. 2022 Jan;36(1):266-278
pubmed: 34709675
Transl Pediatr. 2022 Sep;11(9):1534-1543
pubmed: 36247894
PLoS One. 2021 Jan 14;16(1):e0245209
pubmed: 33444408
Antioxidants (Basel). 2020 Jun 09;9(6):
pubmed: 32526964
Front Med. 2020 Oct;14(5):681-688
pubmed: 32651936
Phytother Res. 2020 Jan;34(1):139-152
pubmed: 31497913
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Biomed Pharmacother. 2020 Jan;121:109604
pubmed: 31733570
Environ Sci Pollut Res Int. 2022 Aug;29(38):57591-57602
pubmed: 35355181
J Ethnopharmacol. 2019 Jun 12;237:266-285
pubmed: 30922854
Am J Chin Med. 2020;48(5):1035-1049
pubmed: 32668970
Kidney Int. 2020 Jul;98(1):209-218
pubmed: 32416116
Nutrients. 2016 Mar 15;8(3):167
pubmed: 26999194
Chin Med. 2019 Dec 18;14:57
pubmed: 31867052
FEBS Open Bio. 2017 Jan 11;7(2):221-236
pubmed: 28174688
Molecules. 2019 Mar 21;24(6):
pubmed: 30901869
Phytomedicine. 2021 Jun;86:153555
pubmed: 33852977
Pharmacol Res. 2015 Sep;99:1-10
pubmed: 25982933
J Clin Med. 2020 Jun 03;9(6):
pubmed: 32503180
Chin J Nat Med. 2021 Jan;19(1):1-11
pubmed: 33516447
J Cheminform. 2014 Apr 16;6:13
pubmed: 24735618
Nat Biotechnol. 2007 Oct;25(10):1110-1
pubmed: 17921993
IEEE/ACM Trans Comput Biol Bioinform. 2019 Jan-Feb;16(1):222-232
pubmed: 29990218
Front Pharmacol. 2022 Feb 04;12:781090
pubmed: 35185537
J Dent Sci. 2022 Oct;17(4):1566-1576
pubmed: 36299308
PLoS One. 2016 Jun 09;11(6):e0156256
pubmed: 27280291
Eur J Intern Med. 2020 Jun;76:14-20
pubmed: 32336612
Indian J Crit Care Med. 2020 Jun;24(6):429-434
pubmed: 32863636
Mediators Inflamm. 2022 Oct 25;2022:4766992
pubmed: 36330380
Comb Chem High Throughput Screen. 2023;26(10):1879-1887
pubmed: 36306462